#Beqvez
LightNews LightNews
profmakris.bsky.social
Pfizer has stopped the global development of Beqvez, their approved #hemophilia B gene therapy. It had a price of $3.5million per dose.
tinyurl.com/ympbesmc
Pfizer stops commercialization of hemophilia gene therapy Beqvez
Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors.
tinyurl.com
February 21, 2025 at 5:18 PM
mixaelslaufer.bsky.social
If y'all aren't selling it anymore, will you open-source the patent, please?

www.reuters.com/business/hea...
Pfizer stops commercialization of hemophilia gene therapy Beqvez
Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors.
www.reuters.com
February 20, 2025 at 11:28 PM
stephmu00mls.bsky.social
$3.5 million per dose -

*NO WONDER* demand was weak!

😳

Pfizer to discontinue its Hemophilia B gene therapy -
"Beqvez" (fidanacogene elaparvovec)

www.medpagetoday.com/hematologyon...
www.medpagetoday.com
February 24, 2025 at 4:46 PM
endpts.com
Pfizer is discontinuing Beqvez, its $3.5M hemophilia B gene therapy, due to limited patient demand. The move marks another challenge for hemophilia gene therapies amid slow adoption.
Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field
Pfizer ends commercialization of Beqvez hemophilia B gene therapy. CEO Kim Phelan of Coalition for Hemophilia B expresses disappointment, notes CSL Behring's Hemgenix remains available.
endpts.com
February 21, 2025 at 2:59 PM
hankgreely.bsky.social
Gene therapy bad news #2, also from
Pharmalittle (& Reuters): "Pfizer will stop global development & commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients & their doctors, Reuters notes. Beqvez is a one-time therapy that was approved in the U.S. last year for
February 21, 2025 at 4:13 PM
drtimos.bsky.social
Signal or noise? > Gene therapy Beqvez can help reduce joint bleeds in
hemophilia B - Hemophilia News Today >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #competitivemarketing #pharma #pharmaceutical #biotech
Gene therapy Beqvez can help reduce joint bleeds in hemophilia B - Hemophilia News Today
Gene therapy Beqvez can help reduce joint bleeds in hemophilia B  Hemophilia News Today
dlvr.it
December 5, 2025 at 9:00 PM
geneticsandsociety.bsky.social
Pfizer will discontinue global development and commercialization of its hemophilia gene therapy Beqvez less than a year after it was approved by the FDA. The move is the latest in a series of steps back from gene therapy development. www.fiercepharma.com...
Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia B product Beqvez. The move leaves no active gene therapy programs in Pfizer's portfolio.
www.fiercepharma.com
March 12, 2025 at 6:00 PM
nolea7.bsky.social
Wasn't Beqvez discontinued by PFE due to low uptake by physicians? 3.5 Million cost per patient -- This is exactly like CRSPR solution just way out of reach for lay person. www.fiercepharma.com/pharma/pfize...
Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | Pfizer is pulling further away from the gene therapy field with its decision to...
www.fiercepharma.com
November 21, 2025 at 11:02 PM
philippbeck.bsky.social
One might see a parallel in Beam/WVE vs Hemgenix;Roctavian;Beqvez/Hympavzi I.e. non-permanent approach was preferred by the market.
March 10, 2025 at 12:57 PM
hemehub.bsky.social
🩸 More insights into In Vivo AAV Gene Therapies for Hemophilia B

#HemophiliaB #GeneTherapy #FactorIX #FIX #EtranacogeneDezaparvovec #FidanacogeneElaparvovec #Beqvez #AAVGeneTherapy #PaduaVariant #Hematology #BleedingDisorders #RareDisease #ClinicalResearch #MedEd #CME #MedicalEducation #HemeHub
July 9, 2026 at 8:00 PM
rravinetto.bsky.social
Feb25: #Pfizer stops commercialization of #hemophilia #gene therapy #Beqvezhigh, priced at $3.5 million.
We need a reflection on therapies #priced millions of dollars for a one-course
@belentarrafeta.bsky.social @elstorreele.bsky.social @elizabethpisani.ternyata.org
www.reuters.com/business/hea...
Pfizer stops commercialization of hemophilia gene therapy Beqvez
Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors.
www.reuters.com
April 4, 2025 at 12:44 PM
benthefidler.bsky.social
New, from @nedpagliarulo.bsky.social: Pfizer has decided to stop selling a treatment called Beqvez in the latest sign of sparse patient interest in gene therapies for hemophilia. #biosky

www.biopharmadive.com/news/pfizer-...
Pfizer stops selling hemophilia gene therapy, citing weak demand
Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for the bleeding condition.
www.biopharmadive.com
February 21, 2025 at 4:12 PM
maxwellmudd.bsky.social
So pfizer has stopped all development of the gene therapy fidanacogene elaparvovec (Beqvez), which treats hemophilia, due to "low interest". I wonder if it was the $3.5 MILLION dollar per dose price tag?
February 21, 2025 at 6:22 PM
caffeineislife.bsky.social
Fantastic that more gene therapies are being approved. Wonder how much this one costs however. Presuming it'd hopefully be covered under provincial health care. www.newswire.ca/news-release...
HEALTH CANADA APPROVES PFIZER CANADA'S GENE THERAPY IN HEMOPHILIA B
/CNW/ - Pfizer Canada ULC announced that Health Canada approved BEQVEZ (fidanacogene elaparvovec), an adeno-associated viral (AAV) vector-based gene therapy...
www.newswire.ca
January 5, 2024 at 4:55 AM
kaz-yos.bsky.social
Pfizer stops selling hemophilia gene therapy, citing weak demand | BioPharma Dive “efforts on later-stage gene therapies for Duchenne muscular dystrophy, hemophilia A and hemophilia B.

Those projects have now all been abandoned.”
Pfizer stops selling hemophilia gene therapy, citing weak demand
Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for the bleeding condition.
buff.ly
February 25, 2025 at 2:53 PM
realtuckfrumper.bsky.social
U.S. approves gene therapy treatment for hemophilia
Pharmaceutical giant Pfizer has received U.S. approval for a gene therapy against a form of hemophilia, a rare and inherited blood clotting disorder, the company said Friday. Beqvez, which is given as a single intravenous infusion, was shown in a…
dlvr.it
April 26, 2024 at 3:13 PM
abovethelaw.com

Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees To Acquisition By Private Equity
https://medcitynews.com/2025/02/bluebird-bio-acquisition-gene-therapy-private-equity-carlyle-sk-capital-blue-pfizer-pfe/

Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees To Acquisition By Private Equity
Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million. Meanwhile, Pfizer continued the culling of its gene therapies with the discontinuation of Beqvez for hemophilia B.
medcitynews.com
February 25, 2025 at 3:12 PM
floydadacrowe.bsky.social
I vividly remember the first time I heard about gene therapy. I was 12, and my hematologist talked about how it could happen 'soon'

This therapy had been on the market since April. That seems a little quick to pull the plug, especially for a treatment we've been waiting for since the early 1990s.
Pfizer stops commercialization of hemophilia gene therapy Beqvez
Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors.
www.reuters.com
February 22, 2025 at 3:29 PM
robbymchale.bsky.social
As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay www.fiercepharma.com/pharma/pfize...
As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay
After Pfizer let limited patient interest get the best of its hemophilia B gene therapy ambitions and discontinued Beqvez, CSL Behring naturally faced the question of whether it can hold its ground | ...
www.fiercepharma.com
April 12, 2025 at 7:16 PM
cyrilpedia.bsky.social
'Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved hemophilia B treatment Beqvez. Bluebird bio, a gene therapy pioneer once valued at $10 billion at its peak, was sold for just $49 million upfront to private equity firms.'
'We will crack gene therapy': Elevidys fallout doesn't dent Roche's hopes for modality
The uncertainty around the future of Elevidys hasn’t destroyed Roche’s belief in the potential of gene therapies, the Swiss company’s head of pharma has told Fierce Biotech, as the pharma continues | ...
www.fiercebiotech.com
July 26, 2025 at 7:23 AM
anne-liseberthier.bsky.social
Pfizer stops selling hemophilia gene therapy, citing weak demand
The company will halt all “further development and commercialization activities” for its hemophilia B treatment Beqvez, a spokesperson confirmed.
www.biopharmadive.com/news/pfizer-...
Pfizer stops selling hemophilia gene therapy, citing weak demand
Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for the bleeding condition.
www.biopharmadive.com
February 21, 2025 at 5:05 PM
informedclearly.bsky.social
FDA approves gene therapies Beqvez & Kebilidi. Payers implement restrictive policies. Million-dollar pricing sparks access debates; CMS initiatives aim to improve affordability. #GeneTherapy #Healthcare #FDA #Pharma informedclearly.com/en/health/31...
Gene Therapy Approvals Ignite Pricing and Access Debate | News | informedclearly
Recent FDA approvals of gene therapies like Beqvez and Kebilidi have sparked debates about million-dollar pricing and equitable access. Payers implement restrictive policies while innovative payment m...
informedclearly.com
December 16, 2025 at 6:38 AM
handgunyoga.bsky.social
Pfizer said it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing “soft demand” from patients and their doctors.

Beqvez was priced at $3.5 million, the same as rival gene therapy Hemgenix and higher than Roctavian, $2.9 million per patient.
Pfizer stops commercialization of hemophilia gene therapy Beqvez
Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors.
www.reuters.com
February 21, 2025 at 6:30 PM
hankgreely.bsky.social
/3 Therapeutics for a hemophilia A gene therapy, citing slow uptake in patients. Doctors have said high cost, logistical issues, & the prospect of potential treatment advances were holding back adoption of gene therapies for hemophilia. Beqvez was priced at $3.5 m in the U.S. during its launch—the
February 21, 2025 at 4:14 PM